Tower Research Capital (TRC)’s Cellebrite CLBT Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14	Buy	+1	New	+$15	﹤0.01%	5068
2025 Q4	–	Sell	-1,179	Closed	-$21.8K	–	5202
2025 Q3	$21.8K	Sell	1,179 -1,059	-47%	-$16.6K	﹤0.01%	3237
2025 Q2	$35.8K	Buy	+2,238	New	+$39.9K	﹤0.01%	3258
2025 Q1	–	Sell	-76	Closed	-$1.67K	–	5266
2024 Q4	$1.67K	Sell	76 -3,405	-98%	-$65.5K	﹤0.01%	4984
2024 Q3	$58.6K	Sell	3,481 -31,536	-90%	-$468K	﹤0.01%	2636
2024 Q2	$418K	Buy	35,017 +29,914	+586%	+$334K	0.01%	1484
2024 Q1	$56.5K	Buy	+5,103	New	+$52.1K	﹤0.01%	2189
2022 Q2	–	Sell	-596	Closed	-$4K	–	6112
2022 Q1	$4K	Buy	+596	New	+$3.95K	﹤0.01%	5186
2021 Q4	–	Sell	-1,363	Closed	-$13K	–	6170
2021 Q3	$13K	Buy	+1,363	New	+$14.2K	﹤0.01%	4068

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tower Research Capital (TRC)'s CLBT Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Cellebrite (CLBT) in Q1 2026: 1 share worth $14. The stake represents ﹤0.01% of the portfolio and ranks #5068 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CLBT as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in CLBT in Q3 2021 and has held it in 9 quarters since. The position peaked at $418K in Q2 2024. 220 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

Tower Research Capital (TRC) held 1 share of Cellebrite worth $14 as of Q1 2026.
Cellebrite was a new Tower Research Capital (TRC) position in Q1 2026.
Cellebrite made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #5068 holding.
Tower Research Capital (TRC) first reported a position in Cellebrite in Q3 2021 and has held it in 9 quarters since.
Tower Research Capital (TRC)'s Cellebrite position peaked at $418K in Q2 2024.
220 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.